Drug Trial Radar · NCT03199586
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Last checked: Nov 19, 2026Latest source record: Jul 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
23
Actual
Start
Dec 21, 2017
Primary completion
May 7, 2020
Study completion May 7, 2020
Sponsor
- Lead sponsor
- Novita Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Translational Drug Development
- First posted
- Jun 27, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1 A: First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on a daily X 28 days followed by a 14 day rest period.
Conditions
- Breast Cancer
- Pancreas Cancer
- Prostate Cancer
- Lung Cancer
- Colon Cancer
- Esophagus Cancer
- Liver Cancer
- Ovary Cancer
- Advanced or Metastatic Treatment-refractory Solid Tumor Malignancies
Interventions
NP-G2-044Drug
capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Establish the safe recommended phase 2 doseTime frame: 24 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
HonorHealth Research Institute
Scottsdale, Arizona
City of Hope National Medical Center
Duarte, California
Memorial Sloan Kettering Hospital
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.